Role of Cytokines and MMPs in Multiple Sclerosis Pathogenesis

A systematic review identified key cytokines (like IL-3, IL-5, IL-6, and MMPs) as critical drivers of neuroinflammation and neurodegeneration in multiple sclerosis (MS). MMP-1 could differentiate early MS from clinically isolated syndrome, while IL-9, IL-10, and IL-13 may be targets for neuroprotective strategies.

Tags: #Biomarkers #Cytokines #Immunomodulation #Neuroprotection
Most relevant to: Neurologist, Immunologist
Source: Read original source (PMID 42794509)

This plain-English summary was written by AI from a published abstract and may contain errors. It is not medical advice. Read the original study and talk to your MS team before making decisions about treatment.

Why it matters

Understanding these biomarkers can enhance knowledge of MS progression and open avenues for innovative treatments, though no clinical efficacy of any interventions is established.

What this does not prove

The findings do not confirm any treatment effectiveness and lack clinical trial data for validation.

Next milestone

No next milestone was established from the available source.

Study facts

Study design: Systematic review
Participants / samples: Not reported
Randomised: Not reported
Controlled: Not reported
Primary endpoint met: Not reported
Relevant MS type: Not reported
Publication date: 2026-09-11
Evidence reviewed: Abstract only
Regulatory approval: Not reported
Research areas: Not classified

Original sources

Primary evidenceCytokines and MMPs in Multiple Sclerosis ↗

Supporting passages (6)

study phaseMultiple sclerosis (MS) is a progressive autoimmune disease of the nervous system (NS).

study designTherefore, this study was conducted to determine the role of selected cytokines and MMPs in the pathogenesis of MS and its potential treatments.

subjectsA precise determination of the role of cytokines and MMPs in the development of MS may contribute to a better understanding of the causes of this disease and to preventing its progression.

publication datePublication date: 2026-09-11

findingsIt was shown that specific cytokines and MMPs act as critical pathophysiological drivers and biomarkers in MS.

limitationsTitle: Selected Cytokines and Matrix Metalloproteinases in Pathogenesis and Treatment of Multiple Sclerosis.

AI assessment, not yet reviewed by a person · version 1 · Community votes are separate from evidence review.